Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
NCT00003761 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003761 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I Trial of Recombinant Vaccinia Virus That Expresses DF3/MUC1 in Patients With Metastatic Adenocarcinoma of the Breast |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | rV-DF3/MUC1 |
| Enrollment | 20 |
| Start date | Mar 3, 1999 |
| Primary completion | Apr 20, 2001 |
| Completion | Oct 19, 2001 |
| First posted | Dec 10, 2003 |
| Last update posted | Feb 15, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: